MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...

Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with ...

Historically, more prostate cancer patients have had a prostatectomy than any other treatment, since radiation as an ...

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer ...

Symptoms of prostate cancer may include needing to urinate more frequently; having to rush to the toilet; straining to ...

Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.

The tragic death comes after Olympic cycling legend Chris Hoy announced he has terminal prostate cancer aged just 48 ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment ...

Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...

Illuccix® is the first and only PSMA-PET1 prostate cancer imaging agent to receive full regulatory approval in Brazil. Illuccix®, after radiolabeling with 68Ga, is a radioactive diagnostic agent ...